NCT06566521 Thoracic Paravertebral Block in Daytime Laparoscopic Partial Adrenalectomy
| NCT ID | NCT06566521 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Shanxi Bethune Hospital |
| Condition | Laparoscopic Adrenalectomy |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2024-08-23 |
| Primary Completion | 2024-10-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 80 participants in total. It began in 2024-08-23 with a primary completion date of 2024-10-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Day surgery refers to the entire diagnostic and therapeutic process completed within 24-48 h, including patient admission, surgery, and discharge. Research by Shariq et al suggested that daytime laparoscopic adrenalectomy was a safe and effective alternative to traditional inpatient treatment. Li et al demonstrated that daytime surgery for laparoscopic partial adrenalectomy could reduce hospital stays, lower medical costs, and optimize healthcare resource utilization. The day surgery has put forward higher requirements for the management of perioperative anesthesia, in which the postoperative multimodal analgesia is particularly important.Thoracic paravertebral block (TPVB) is a regional block technique in which local anaesthetics can be injected into paravertebral space to block the ipsilateral sympathetic and somatosensory nerves. TPVB single point injection can achieve sensory block of 3-6 spinal ganglia on one side, with minimal impact on respiratory, gastrointestinal and bladder function. Especially, TPVB does not affect motor nerve, which enable patients to perform painless functional exercise shortly after surgery, promote rapid recovery, and enhance satisfaction and comfort. A large number of previous studies have shown that TPVB had become increasingly popular for postoperative analgesia after thoracic or breast surgery. However, to our knowledge, few studies to date have investigated the application of TPVB in daytime adrenal surgery. Therefore, we conducted this randomized clinical trial to examine the effect of TPVB on postoperative analgesia and the quality of recovery in patients following daytime laparoscopic partial adrenalectomy.
Eligibility Criteria
Inclusion Criteria: * Aged 18 to70 years * Body Mass Index (BMI) 18.5 to 30 kg/m² * American Society of Anesthesiologists (ASA) grade I to II classification * unilateral non-functional adrenal adenoma with a tumor diameter greater than 20mm Exclusion Criteria: * Patients with peripheral nervous system disease * Patients with spinal deformity or surgery * Patients with puncture site infection or coagulation abnormalities * Patients with history of postoperative nausea and vomiting or allergy to local anesthetics * Patients with unstable mental illness or refusal to participate
Contact & Investigator
Jian-Wen Zhang, MD
PRINCIPAL INVESTIGATOR
Shanxi Bethune Hospital
Frequently Asked Questions
Who can join the NCT06566521 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Laparoscopic Adrenalectomy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06566521 currently recruiting?
Yes, NCT06566521 is actively recruiting participants. Contact the research team at zjw030001@126.com for enrollment information.
Where is the NCT06566521 trial being conducted?
This trial is being conducted at Taiyuan, China.
Who is sponsoring the NCT06566521 clinical trial?
NCT06566521 is sponsored by Shanxi Bethune Hospital. The principal investigator is Jian-Wen Zhang, MD at Shanxi Bethune Hospital. The trial plans to enroll 80 participants.